New Breakthrough in Aggressive Breast Cancer
There’s new hope for patients with aggressive triple-negative breast cancer. Recent research shows that combining chemotherapy with the immunotherapy drug pembrolizumab before and after surgery can significantly improve survival rates.
This breakthrough treatment, highlighted in the KEYNOTE-522 trial and published in the New England Journal of Medicine, could change how this challenging cancer is treated.
Reported by
Reviewed by
You May Also Like
How Well Does Orforglipron (Foundayo) Actually Work?
How well does Orforglipron, also called Foundayo, actually work? To understand how well it works, researchers ran a large clinical trial with over 3,100 adults with obesity.
What Causes a Stroke?
A stroke happens when blood flow to part of the brain is blocked or when a blood vessel in the brain bursts. Without oxygen-rich blood, brain cells begin to die within minutes.